Zura Bio Limited (NASDAQ:ZURA) Shares Purchased by JPMorgan Chase & Co.

JPMorgan Chase & Co. boosted its holdings in shares of Zura Bio Limited (NASDAQ:ZURA - Free Report) by 12,060.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,633,185 shares of the company's stock after acquiring an additional 2,611,532 shares during the quarter. JPMorgan Chase & Co. owned about 4.03% of Zura Bio worth $6,583,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Geode Capital Management LLC boosted its position in shares of Zura Bio by 70.6% during the third quarter. Geode Capital Management LLC now owns 912,625 shares of the company's stock worth $3,706,000 after buying an additional 377,545 shares during the period. Barclays PLC boosted its position in shares of Zura Bio by 777.1% during the third quarter. Barclays PLC now owns 64,061 shares of the company's stock worth $260,000 after buying an additional 56,757 shares during the period. Rhumbline Advisers boosted its position in shares of Zura Bio by 37.3% during the fourth quarter. Rhumbline Advisers now owns 37,657 shares of the company's stock worth $94,000 after buying an additional 10,231 shares during the period. State Street Corp boosted its position in shares of Zura Bio by 47.5% during the third quarter. State Street Corp now owns 395,059 shares of the company's stock worth $1,604,000 after buying an additional 127,300 shares during the period. Finally, SG Americas Securities LLC boosted its holdings in Zura Bio by 51.6% in the fourth quarter. SG Americas Securities LLC now owns 23,005 shares of the company's stock valued at $58,000 after purchasing an additional 7,828 shares during the period. Institutional investors and hedge funds own 61.14% of the company's stock.

Analysts Set New Price Targets

A number of research firms recently issued reports on ZURA. Oppenheimer reiterated an "outperform" rating and issued a $19.00 target price (down from $20.00) on shares of Zura Bio in a report on Wednesday, March 26th. Guggenheim reiterated a "buy" rating and issued a $15.00 target price on shares of Zura Bio in a report on Wednesday, March 26th. HC Wainwright reaffirmed a "buy" rating on shares of Zura Bio in a research report on Thursday, April 3rd. Finally, Chardan Capital cut their target price on Zura Bio from $12.00 to $10.00 and set a "buy" rating on the stock in a research report on Wednesday, March 26th. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $14.67.

Zura Bio Stock Up 4.0 %

Shares of Zura Bio stock traded up $0.06 on Wednesday, hitting $1.55. The company's stock had a trading volume of 73,097 shares, compared to its average volume of 389,314. Zura Bio Limited has a 52-week low of $0.97 and a 52-week high of $6.35. The firm has a fifty day moving average price of $1.28 and a 200-day moving average price of $2.37. The company has a market capitalization of $105.98 million, a P/E ratio of -2.92 and a beta of 0.08.

Zura Bio (NASDAQ:ZURA - Get Free Report) last announced its earnings results on Tuesday, March 25th. The company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.09. The firm had revenue of $0.00 million during the quarter. As a group, analysts expect that Zura Bio Limited will post -0.65 earnings per share for the current year.

Zura Bio Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.